JP2007526290A - 新規のリポキシゲナーゼインヒビターの使用 - Google Patents
新規のリポキシゲナーゼインヒビターの使用 Download PDFInfo
- Publication number
- JP2007526290A JP2007526290A JP2007501342A JP2007501342A JP2007526290A JP 2007526290 A JP2007526290 A JP 2007526290A JP 2007501342 A JP2007501342 A JP 2007501342A JP 2007501342 A JP2007501342 A JP 2007501342A JP 2007526290 A JP2007526290 A JP 2007526290A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- phenyl
- formula
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 235
- 150000003839 salts Chemical class 0.000 claims abstract description 40
- 239000003814 drug Substances 0.000 claims abstract description 22
- 206010061218 Inflammation Diseases 0.000 claims abstract description 21
- 230000004054 inflammatory process Effects 0.000 claims abstract description 21
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 17
- 102000003820 Lipoxygenases Human genes 0.000 claims abstract description 16
- 108090000128 Lipoxygenases Proteins 0.000 claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 102000009515 Arachidonate 15-Lipoxygenase Human genes 0.000 claims abstract description 13
- 108010048907 Arachidonate 15-lipoxygenase Proteins 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 153
- -1 methylenedioxy, difluoromethylenedioxy Chemical group 0.000 claims description 142
- 125000000217 alkyl group Chemical group 0.000 claims description 101
- 125000001424 substituent group Chemical group 0.000 claims description 82
- 125000003118 aryl group Chemical group 0.000 claims description 69
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 60
- 125000000623 heterocyclic group Chemical group 0.000 claims description 49
- 238000006243 chemical reaction Methods 0.000 claims description 33
- 125000005843 halogen group Chemical group 0.000 claims description 31
- 125000004429 atom Chemical group 0.000 claims description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- 125000001153 fluoro group Chemical group F* 0.000 claims description 17
- 125000004122 cyclic group Chemical group 0.000 claims description 15
- 208000024891 symptom Diseases 0.000 claims description 15
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 125000001246 bromo group Chemical group Br* 0.000 claims description 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 11
- 125000004076 pyridyl group Chemical group 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 9
- 208000006673 asthma Diseases 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 9
- 125000001544 thienyl group Chemical group 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 230000002757 inflammatory effect Effects 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 8
- 125000006850 spacer group Chemical group 0.000 claims description 8
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 7
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 claims description 6
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 6
- 125000002757 morpholinyl group Chemical group 0.000 claims description 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 5
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 4
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 4
- 206010065390 Inflammatory pain Diseases 0.000 claims description 4
- 206010037660 Pyrexia Diseases 0.000 claims description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 3
- 206010010741 Conjunctivitis Diseases 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039705 Scleritis Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 2
- 239000013066 combination product Substances 0.000 claims description 2
- 229940127555 combination product Drugs 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 201000004614 iritis Diseases 0.000 claims description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 238000007142 ring opening reaction Methods 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 127
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 65
- 239000007787 solid Substances 0.000 description 48
- 239000000843 powder Substances 0.000 description 45
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- 239000013078 crystal Substances 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 239000000203 mixture Substances 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 22
- 239000000543 intermediate Substances 0.000 description 17
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 150000002923 oximes Chemical class 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 229940114079 arachidonic acid Drugs 0.000 description 6
- 235000021342 arachidonic acid Nutrition 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 6
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 6
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Substances [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 4
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- MLNKXLRYCLKJSS-RMKNXTFCSA-N (2e)-2-hydroxyimino-1-phenylethanone Chemical compound O\N=C\C(=O)C1=CC=CC=C1 MLNKXLRYCLKJSS-RMKNXTFCSA-N 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 3
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 3
- 102100022278 Arachidonate 5-lipoxygenase-activating protein Human genes 0.000 description 3
- 101000755875 Homo sapiens Arachidonate 5-lipoxygenase-activating protein Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000009109 curative therapy Methods 0.000 description 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- VFWRGKJLLYDFBY-UHFFFAOYSA-N silver;hydrate Chemical compound O.[Ag].[Ag] VFWRGKJLLYDFBY-UHFFFAOYSA-N 0.000 description 3
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 2
- YXZFFTJAHVMMLF-UHFFFAOYSA-N 1-bromo-3-methylbutane Chemical compound CC(C)CCBr YXZFFTJAHVMMLF-UHFFFAOYSA-N 0.000 description 2
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 2
- GUQPDBSKLSISJW-UHFFFAOYSA-N 2,5-dichloro-N-[(2-hydroxyimino-1-phenylethylidene)amino]benzamide Chemical compound C=1C=CC=CC=1C(C=NO)=NNC(=O)C1=CC(Cl)=CC=C1Cl GUQPDBSKLSISJW-UHFFFAOYSA-N 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- QETLLHJNOMAUAS-UHFFFAOYSA-N 3-chloro-N-[[1-(3-chlorophenyl)-2-hydroxyiminoethylidene]amino]benzamide Chemical compound C=1C=CC(Cl)=CC=1C(C=NO)=NNC(=O)C1=CC=CC(Cl)=C1 QETLLHJNOMAUAS-UHFFFAOYSA-N 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- PZSFCYMMGSGNNA-UHFFFAOYSA-N N-[(2-hydroxyimino-1-phenylethylidene)amino]benzamide Chemical compound C=1C=CC=CC=1C(C=NO)=NNC(=O)C1=CC=CC=C1 PZSFCYMMGSGNNA-UHFFFAOYSA-N 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 0 *C(CCC(*)=O)=NNC(*)=O Chemical compound *C(CCC(*)=O)=NNC(*)=O 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- FLOJNXXFMHCMMR-UHFFFAOYSA-N 1,3-dithiolanyl Chemical group [CH]1SCCS1 FLOJNXXFMHCMMR-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
- YRUDEXOYOJEORP-UHFFFAOYSA-N 1-(2-bromophenyl)-2-hydroxyiminoethanone Chemical compound ON=CC(=O)C1=CC=CC=C1Br YRUDEXOYOJEORP-UHFFFAOYSA-N 0.000 description 1
- DFDWWIDSKJWWMT-UHFFFAOYSA-N 1-(2-butoxyphenyl)-2-hydroxyiminoethanone Chemical compound CCCCOC1=CC=CC=C1C(=O)C=NO DFDWWIDSKJWWMT-UHFFFAOYSA-N 0.000 description 1
- DDPDPPHQCHWNJJ-UHFFFAOYSA-N 1-(2-fluorophenyl)-2-hydroxyiminoethanone Chemical compound ON=CC(=O)C1=CC=CC=C1F DDPDPPHQCHWNJJ-UHFFFAOYSA-N 0.000 description 1
- YJVZGCUDDGHDMM-UHFFFAOYSA-N 1-(3-chlorophenyl)-2-hydroxyiminoethanone Chemical compound ON=CC(=O)C1=CC=CC(Cl)=C1 YJVZGCUDDGHDMM-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- BFWYTORDSFIVKP-VAEKSGALSA-N 15(S)-HPETE Chemical compound CCCCC[C@H](OO)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O BFWYTORDSFIVKP-VAEKSGALSA-N 0.000 description 1
- JSFATNQSLKRBCI-UHFFFAOYSA-N 15-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC(O)C=CC=CCC=CCC=CCCCC(O)=O JSFATNQSLKRBCI-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- FXHPIWOJNJJPCD-UHFFFAOYSA-N 2,4-dichloro-N-[(2-hydroxyimino-1-phenylethylidene)amino]benzamide Chemical compound C=1C=CC=CC=1C(C=NO)=NNC(=O)C1=CC=C(Cl)C=C1Cl FXHPIWOJNJJPCD-UHFFFAOYSA-N 0.000 description 1
- KXPWZHNFXMPNPT-UHFFFAOYSA-N 2-amino-N-[(2-hydroxyimino-1-phenylethylidene)amino]benzamide Chemical compound NC1=CC=CC=C1C(=O)NN=C(C=NO)C1=CC=CC=C1 KXPWZHNFXMPNPT-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- VNTXXALGNQDCNI-UHFFFAOYSA-N 2-bromo-N-[[1-(2-fluorophenyl)-2-hydroxyiminoethylidene]amino]benzamide Chemical compound C=1C=CC=C(F)C=1C(C=NO)=NNC(=O)C1=CC=CC=C1Br VNTXXALGNQDCNI-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- AQCWDDUCAQTGFP-UHFFFAOYSA-N 2-fluoro-N-[(2-hydroxyimino-1-phenylethylidene)amino]benzamide Chemical compound C=1C=CC=CC=1C(C=NO)=NNC(=O)C1=CC=CC=C1F AQCWDDUCAQTGFP-UHFFFAOYSA-N 0.000 description 1
- DAIRJQLFQRCBKA-UHFFFAOYSA-N 2-hydroxyimino-1-(4-phenoxyphenyl)ethanone Chemical compound C1=CC(C(=O)C=NO)=CC=C1OC1=CC=CC=C1 DAIRJQLFQRCBKA-UHFFFAOYSA-N 0.000 description 1
- DLVKKEWLLCWBBY-UHFFFAOYSA-N 2-hydroxyimino-1-[2-(trifluoromethyl)phenyl]ethanone Chemical compound ON=CC(=O)C1=CC=CC=C1C(F)(F)F DLVKKEWLLCWBBY-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- GDBNHMMONLDLMB-UHFFFAOYSA-N 3,4-dichloro-N-[[1-(3,4-dichlorophenyl)-2-hydroxyiminoethylidene]amino]benzamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(C=NO)=NNC(=O)C1=CC=C(Cl)C(Cl)=C1 GDBNHMMONLDLMB-UHFFFAOYSA-N 0.000 description 1
- GJZTWIIDLFYTMU-UHFFFAOYSA-N 3,4-dichloro-N-[[1-(3-chlorophenyl)-2-hydroxyiminoethylidene]amino]benzamide Chemical compound C=1C=CC(Cl)=CC=1C(C=NO)=NNC(=O)C1=CC=C(Cl)C(Cl)=C1 GJZTWIIDLFYTMU-UHFFFAOYSA-N 0.000 description 1
- OXBTXAGPPIXYKH-UHFFFAOYSA-N 3,5-dibromo-N-[[1-(3-chlorophenyl)-2-hydroxyiminoethylidene]amino]benzamide Chemical compound C=1C=CC(Cl)=CC=1C(C=NO)=NNC(=O)C1=CC(Br)=CC(Br)=C1 OXBTXAGPPIXYKH-UHFFFAOYSA-N 0.000 description 1
- ZCNTZQZUTMWNAI-UHFFFAOYSA-N 3,5-dichloro-N-[[1-(3-chlorophenyl)-2-hydroxyiminoethylidene]amino]benzamide Chemical compound C=1C=CC(Cl)=CC=1C(C=NO)=NNC(=O)C1=CC(Cl)=CC(Cl)=C1 ZCNTZQZUTMWNAI-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- YDJZABGRFZSSIX-UHFFFAOYSA-N 3-(dimethylsulfamoyl)-N-[(2-hydroxyimino-1-phenylethylidene)amino]benzamide Chemical compound CN(C)S(=O)(=O)C1=CC=CC(C(=O)NN=C(C=NO)C=2C=CC=CC=2)=C1 YDJZABGRFZSSIX-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- OBDGRZZECYPOMQ-UHFFFAOYSA-N 3-amino-N-[(2-hydroxyimino-1-phenylethylidene)amino]benzamide Chemical compound NC1=CC=CC(C(=O)NN=C(C=NO)C=2C=CC=CC=2)=C1 OBDGRZZECYPOMQ-UHFFFAOYSA-N 0.000 description 1
- FCRSUMCPUGMFJP-UHFFFAOYSA-N 3-bromo-N-[(2-hydroxyimino-1-pyridin-2-ylethylidene)amino]benzamide Chemical compound C=1C=CC=NC=1C(C=NO)=NNC(=O)C1=CC=CC(Br)=C1 FCRSUMCPUGMFJP-UHFFFAOYSA-N 0.000 description 1
- OCZJKRGUGMRJSW-UHFFFAOYSA-N 3-bromo-N-[[1-(2-chlorophenyl)-2-hydroxyiminoethylidene]amino]benzamide Chemical compound C=1C=CC=C(Cl)C=1C(C=NO)=NNC(=O)C1=CC=CC(Br)=C1 OCZJKRGUGMRJSW-UHFFFAOYSA-N 0.000 description 1
- QAMIUSAWUXXDDK-UHFFFAOYSA-N 3-bromo-N-[[1-(3-chlorophenyl)-2-hydroxyiminoethylidene]amino]benzamide Chemical compound C=1C=CC(Cl)=CC=1C(C=NO)=NNC(=O)C1=CC=CC(Br)=C1 QAMIUSAWUXXDDK-UHFFFAOYSA-N 0.000 description 1
- BAKVLXBTHZPCTH-UHFFFAOYSA-N 3-bromo-N-[[1-(4-bromophenyl)-2-hydroxyiminoethylidene]amino]benzamide Chemical compound C=1C=C(Br)C=CC=1C(C=NO)=NNC(=O)C1=CC=CC(Br)=C1 BAKVLXBTHZPCTH-UHFFFAOYSA-N 0.000 description 1
- HOFOCCHCGCWULQ-UHFFFAOYSA-N 3-bromo-N-[[2-hydroxyimino-1-(2-methoxyphenyl)ethylidene]amino]benzamide Chemical compound COC1=CC=CC=C1C(C=NO)=NNC(=O)C1=CC=CC(Br)=C1 HOFOCCHCGCWULQ-UHFFFAOYSA-N 0.000 description 1
- XZWIDBDUVNWENQ-UHFFFAOYSA-N 3-bromo-N-[[2-hydroxyimino-1-(3-hydroxyphenyl)ethylidene]amino]benzamide Chemical compound C=1C=CC(O)=CC=1C(C=NO)=NNC(=O)C1=CC=CC(Br)=C1 XZWIDBDUVNWENQ-UHFFFAOYSA-N 0.000 description 1
- DJSXOSDNRZWYOS-UHFFFAOYSA-N 3-bromo-N-[[2-hydroxyimino-1-(3-methoxyphenyl)ethylidene]amino]benzamide Chemical compound COC1=CC=CC(C(C=NO)=NNC(=O)C=2C=C(Br)C=CC=2)=C1 DJSXOSDNRZWYOS-UHFFFAOYSA-N 0.000 description 1
- ZHHOGEUPKCSBKM-UHFFFAOYSA-N 3-bromo-N-[[2-hydroxyimino-1-(4-methoxyphenyl)ethylidene]amino]benzamide Chemical compound C1=CC(OC)=CC=C1C(C=NO)=NNC(=O)C1=CC=CC(Br)=C1 ZHHOGEUPKCSBKM-UHFFFAOYSA-N 0.000 description 1
- MUBVEGVHVZFJEH-UHFFFAOYSA-N 3-bromo-N-[[2-hydroxyimino-1-(4-phenoxyphenyl)ethylidene]amino]benzamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(C=NO)=NNC(=O)C1=CC=CC(Br)=C1 MUBVEGVHVZFJEH-UHFFFAOYSA-N 0.000 description 1
- KAHMCWYNYJZBOC-UHFFFAOYSA-N 3-bromo-N-[[2-hydroxyimino-1-[3-(methanesulfonamido)phenyl]ethylidene]amino]benzamide Chemical compound CS(=O)(=O)NC1=CC=CC(C(C=NO)=NNC(=O)C=2C=C(Br)C=CC=2)=C1 KAHMCWYNYJZBOC-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- MZDXHMIXPRUIDJ-UHFFFAOYSA-N 3-chloro-N-[(2-hydroxyimino-1-phenylethylidene)amino]benzamide Chemical compound C=1C=CC=CC=1C(C=NO)=NNC(=O)C1=CC=CC(Cl)=C1 MZDXHMIXPRUIDJ-UHFFFAOYSA-N 0.000 description 1
- HSVJNLDSLLGVGT-UHFFFAOYSA-N 3-chloro-N-[(2-hydroxyimino-1-phenylpropylidene)amino]benzamide Chemical compound C=1C=CC=CC=1C(C(=NO)C)=NNC(=O)C1=CC=CC(Cl)=C1 HSVJNLDSLLGVGT-UHFFFAOYSA-N 0.000 description 1
- CFJUFTKSMQHLNZ-UHFFFAOYSA-N 3-chloro-N-[(2-hydroxyimino-1-pyridin-4-ylethylidene)amino]benzamide Chemical compound C=1C=NC=CC=1C(C=NO)=NNC(=O)C1=CC=CC(Cl)=C1 CFJUFTKSMQHLNZ-UHFFFAOYSA-N 0.000 description 1
- IAASJHYSPTVWKZ-UHFFFAOYSA-N 3-chloro-N-[(2-hydroxyimino-1-quinoxalin-2-ylethylidene)amino]benzamide Chemical compound C=1N=C2C=CC=CC2=NC=1C(C=NO)=NNC(=O)C1=CC=CC(Cl)=C1 IAASJHYSPTVWKZ-UHFFFAOYSA-N 0.000 description 1
- INVYKFNFQUEDCU-UHFFFAOYSA-N 3-chloro-N-[[1-(2-fluorophenyl)-2-hydroxyiminoethylidene]amino]benzamide Chemical compound C=1C=CC=C(F)C=1C(C=NO)=NNC(=O)C1=CC=CC(Cl)=C1 INVYKFNFQUEDCU-UHFFFAOYSA-N 0.000 description 1
- WIWNDQNEBZUBKP-UHFFFAOYSA-N 3-chloro-N-[[1-(3-chloro-4-fluorophenyl)-2-hydroxyiminoethylidene]amino]benzamide Chemical compound C=1C=C(F)C(Cl)=CC=1C(C=NO)=NNC(=O)C1=CC=CC(Cl)=C1 WIWNDQNEBZUBKP-UHFFFAOYSA-N 0.000 description 1
- JSEUKTGDZIFHHM-UHFFFAOYSA-N 3-chloro-N-[[1-(3-fluorophenyl)-2-hydroxyiminoethylidene]amino]benzamide Chemical compound C=1C=CC(F)=CC=1C(C=NO)=NNC(=O)C1=CC=CC(Cl)=C1 JSEUKTGDZIFHHM-UHFFFAOYSA-N 0.000 description 1
- NUZDGIQPBNWXCY-UHFFFAOYSA-N 3-chloro-N-[[1-(4-cyanophenyl)-2-hydroxyiminoethylidene]amino]benzamide Chemical compound C=1C=C(C#N)C=CC=1C(C=NO)=NNC(=O)C1=CC=CC(Cl)=C1 NUZDGIQPBNWXCY-UHFFFAOYSA-N 0.000 description 1
- PZLZIDZZHOUOEH-UHFFFAOYSA-N 3-chloro-N-[[1-[4-(dimethylamino)phenyl]-2-hydroxyiminoethylidene]amino]benzamide Chemical compound C1=CC(N(C)C)=CC=C1C(C=NO)=NNC(=O)C1=CC=CC(Cl)=C1 PZLZIDZZHOUOEH-UHFFFAOYSA-N 0.000 description 1
- MSIBVAAHCIFWJL-UHFFFAOYSA-N 3-chloro-N-[[2-hydroxyimino-1-(3-methylphenyl)ethylidene]amino]benzamide Chemical compound CC1=CC=CC(C(C=NO)=NNC(=O)C=2C=C(Cl)C=CC=2)=C1 MSIBVAAHCIFWJL-UHFFFAOYSA-N 0.000 description 1
- PTNZFFGAGNLXJM-UHFFFAOYSA-N 3-chloro-N-[[2-hydroxyimino-1-(3-nitrophenyl)ethylidene]amino]benzamide Chemical compound C=1C=CC([N+]([O-])=O)=CC=1C(C=NO)=NNC(=O)C1=CC=CC(Cl)=C1 PTNZFFGAGNLXJM-UHFFFAOYSA-N 0.000 description 1
- IBVYCGQFUARGGT-UHFFFAOYSA-N 3-chloro-N-[[2-hydroxyimino-1-(4-morpholin-4-ylphenyl)ethylidene]amino]benzamide Chemical compound C=1C=C(N2CCOCC2)C=CC=1C(C=NO)=NNC(=O)C1=CC=CC(Cl)=C1 IBVYCGQFUARGGT-UHFFFAOYSA-N 0.000 description 1
- GPAXVDADIZWFIR-UHFFFAOYSA-N 3-chloro-N-[[2-hydroxyimino-1-(4-phenoxyphenyl)ethylidene]amino]benzamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(C=NO)=NNC(=O)C1=CC=CC(Cl)=C1 GPAXVDADIZWFIR-UHFFFAOYSA-N 0.000 description 1
- GOXHINDSFHHDLX-UHFFFAOYSA-N 3-chloro-N-[[2-hydroxyimino-1-[3-(trifluoromethyl)phenyl]ethylidene]amino]benzamide Chemical compound C=1C=CC(C(F)(F)F)=CC=1C(C=NO)=NNC(=O)C1=CC=CC(Cl)=C1 GOXHINDSFHHDLX-UHFFFAOYSA-N 0.000 description 1
- SOPRBXSNXWQVMN-UHFFFAOYSA-N 3-chloro-n-[[2-(3-methylbutoxyimino)-1-phenylethylidene]amino]benzamide Chemical compound C=1C=CC=CC=1C(C=NOCCC(C)C)=NNC(=O)C1=CC=CC(Cl)=C1 SOPRBXSNXWQVMN-UHFFFAOYSA-N 0.000 description 1
- YKFYONLQHNEHCV-UHFFFAOYSA-N 3-hydroxy-N-[(2-hydroxyimino-1-phenylethylidene)amino]benzamide Chemical compound C=1C=CC=CC=1C(C=NO)=NNC(=O)C1=CC=CC(O)=C1 YKFYONLQHNEHCV-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- DNODUKWAFLTODU-UHFFFAOYSA-N 4-bromo-N-[(2-hydroxyimino-1-phenylethylidene)amino]benzamide Chemical compound C=1C=CC=CC=1C(C=NO)=NNC(=O)C1=CC=C(Br)C=C1 DNODUKWAFLTODU-UHFFFAOYSA-N 0.000 description 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
- BOSNZCAGENXIHK-UHFFFAOYSA-N 4-fluoro-N-[(2-hydroxyimino-1-phenylethylidene)amino]benzamide Chemical compound C=1C=CC=CC=1C(C=NO)=NNC(=O)C1=CC=C(F)C=C1 BOSNZCAGENXIHK-UHFFFAOYSA-N 0.000 description 1
- CVTIZADVQFTUOF-UHFFFAOYSA-N 4-tert-butyl-N-[[2-hydroxyimino-1-(4-phenoxyphenyl)ethylidene]amino]benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)NN=C(C=NO)C(C=C1)=CC=C1OC1=CC=CC=C1 CVTIZADVQFTUOF-UHFFFAOYSA-N 0.000 description 1
- LNXCHJKBDDPYEM-UHFFFAOYSA-N 4-tert-butyl-N-[[2-hydroxyimino-1-[3-(trifluoromethyl)phenyl]ethylidene]amino]benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)NN=C(C=NO)C1=CC=CC(C(F)(F)F)=C1 LNXCHJKBDDPYEM-UHFFFAOYSA-N 0.000 description 1
- 125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 description 1
- 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 description 1
- 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 description 1
- 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 description 1
- HCJRWTCZYMSAMK-UHFFFAOYSA-N 5-bromo-N-[(2-hydroxyimino-1-phenylethylidene)amino]pyridine-3-carboxamide Chemical compound C=1C=CC=CC=1C(C=NO)=NNC(=O)C1=CN=CC(Br)=C1 HCJRWTCZYMSAMK-UHFFFAOYSA-N 0.000 description 1
- YUBQNOFNOWSDJE-UHFFFAOYSA-N 5-bromo-N-[[1-(3-chlorophenyl)-2-hydroxyiminoethylidene]amino]pyridine-3-carboxamide Chemical compound C=1C=CC(Cl)=CC=1C(C=NO)=NNC(=O)C1=CN=CC(Br)=C1 YUBQNOFNOWSDJE-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- OLKRVSJWAZYBNE-UHFFFAOYSA-N 6-chloro-N-[(2-hydroxyimino-1-phenylethylidene)amino]pyridine-3-carboxamide Chemical compound C=1C=CC=CC=1C(C=NO)=NNC(=O)C1=CC=C(Cl)N=C1 OLKRVSJWAZYBNE-UHFFFAOYSA-N 0.000 description 1
- TWYMBCKNRYXVHY-UHFFFAOYSA-N 6-chloro-N-[[1-(3-chlorophenyl)-2-hydroxyiminoethylidene]amino]pyridine-2-carboxamide Chemical compound C=1C=CC(Cl)=CC=1C(C=NO)=NNC(=O)C1=CC=CC(Cl)=N1 TWYMBCKNRYXVHY-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 102000011730 Arachidonate 12-Lipoxygenase Human genes 0.000 description 1
- 108010076676 Arachidonate 12-lipoxygenase Proteins 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- ZGUUREJRTMBRNO-UHFFFAOYSA-N N-[(2-hydroxyimino-1-phenylethylidene)amino]-1,3,5-trimethylpyrazole-4-carboxamide Chemical compound CC1=NN(C)C(C)=C1C(=O)NN=C(C=NO)C1=CC=CC=C1 ZGUUREJRTMBRNO-UHFFFAOYSA-N 0.000 description 1
- TYISATDOCZMDLX-UHFFFAOYSA-N N-[(2-hydroxyimino-1-phenylethylidene)amino]-2-methoxybenzamide Chemical compound COC1=CC=CC=C1C(=O)NN=C(C=NO)C1=CC=CC=C1 TYISATDOCZMDLX-UHFFFAOYSA-N 0.000 description 1
- XFIXXMDAPWWXFN-UHFFFAOYSA-N N-[(2-hydroxyimino-1-phenylethylidene)amino]-2-methylbenzamide Chemical compound CC1=CC=CC=C1C(=O)NN=C(C=NO)C1=CC=CC=C1 XFIXXMDAPWWXFN-UHFFFAOYSA-N 0.000 description 1
- FIJNGWFANVXNCR-UHFFFAOYSA-N N-[(2-hydroxyimino-1-phenylethylidene)amino]-2-nitrobenzamide Chemical compound C=1C=CC=CC=1C(C=NO)=NNC(=O)C1=CC=CC=C1[N+]([O-])=O FIJNGWFANVXNCR-UHFFFAOYSA-N 0.000 description 1
- ZLMPTFBJFRIODF-UHFFFAOYSA-N N-[(2-hydroxyimino-1-phenylethylidene)amino]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NN=C(C=NO)C=2C=CC=CC=2)=C1 ZLMPTFBJFRIODF-UHFFFAOYSA-N 0.000 description 1
- AOBZFUPKTIEOJB-UHFFFAOYSA-N N-[(2-hydroxyimino-1-phenylethylidene)amino]-3,4-dimethoxybenzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NN=C(C=NO)C1=CC=CC=C1 AOBZFUPKTIEOJB-UHFFFAOYSA-N 0.000 description 1
- KKALGRRYBOUUGU-UHFFFAOYSA-N N-[(2-hydroxyimino-1-phenylethylidene)amino]-3-(trifluoromethyl)benzamide Chemical compound C=1C=CC=CC=1C(C=NO)=NNC(=O)C1=CC=CC(C(F)(F)F)=C1 KKALGRRYBOUUGU-UHFFFAOYSA-N 0.000 description 1
- RILAPDOBZZFKQS-UHFFFAOYSA-N N-[(2-hydroxyimino-1-phenylethylidene)amino]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NN=C(C=NO)C=2C=CC=CC=2)=C1 RILAPDOBZZFKQS-UHFFFAOYSA-N 0.000 description 1
- KJVVPGOVICZVOP-UHFFFAOYSA-N N-[(2-hydroxyimino-1-phenylethylidene)amino]-3-methylbenzamide Chemical compound CC1=CC=CC(C(=O)NN=C(C=NO)C=2C=CC=CC=2)=C1 KJVVPGOVICZVOP-UHFFFAOYSA-N 0.000 description 1
- FEQMHAZBBLKDFY-UHFFFAOYSA-N N-[(2-hydroxyimino-1-phenylethylidene)amino]-4-(trifluoromethyl)benzamide Chemical compound C=1C=CC=CC=1C(C=NO)=NNC(=O)C1=CC=C(C(F)(F)F)C=C1 FEQMHAZBBLKDFY-UHFFFAOYSA-N 0.000 description 1
- JDDNVIGSELMRPI-UHFFFAOYSA-N N-[(2-hydroxyimino-1-phenylethylidene)amino]-4-methoxybenzamide Chemical compound C1=CC(OC)=CC=C1C(=O)NN=C(C=NO)C1=CC=CC=C1 JDDNVIGSELMRPI-UHFFFAOYSA-N 0.000 description 1
- NNHHCWCZGJRNOK-UHFFFAOYSA-N N-[(2-hydroxyimino-1-phenylethylidene)amino]-4-methylbenzamide Chemical compound C1=CC(C)=CC=C1C(=O)NN=C(C=NO)C1=CC=CC=C1 NNHHCWCZGJRNOK-UHFFFAOYSA-N 0.000 description 1
- SNKNLVUJPIIHHP-UHFFFAOYSA-N N-[(2-hydroxyimino-1-phenylethylidene)amino]-4-nitrobenzamide Chemical compound C=1C=CC=CC=1C(C=NO)=NNC(=O)C1=CC=C([N+]([O-])=O)C=C1 SNKNLVUJPIIHHP-UHFFFAOYSA-N 0.000 description 1
- GRCJDOKFEIXTKY-UHFFFAOYSA-N N-[(2-hydroxyimino-1-phenylethylidene)amino]-5-methyl-1H-pyrazole-3-carboxamide Chemical compound N1C(C)=CC(C(=O)NN=C(C=NO)C=2C=CC=CC=2)=N1 GRCJDOKFEIXTKY-UHFFFAOYSA-N 0.000 description 1
- LXZUBHWPDKUMHL-UHFFFAOYSA-N N-[(2-hydroxyimino-1-phenylethylidene)amino]-6-methylpyridine-2-carboxamide Chemical compound CC1=CC=CC(C(=O)NN=C(C=NO)C=2C=CC=CC=2)=N1 LXZUBHWPDKUMHL-UHFFFAOYSA-N 0.000 description 1
- SHRHWUXIBOVTRF-UHFFFAOYSA-N N-[(2-hydroxyimino-1-phenylethylidene)amino]-6-methylpyridine-3-carboxamide Chemical compound C1=NC(C)=CC=C1C(=O)NN=C(C=NO)C1=CC=CC=C1 SHRHWUXIBOVTRF-UHFFFAOYSA-N 0.000 description 1
- JOHRDWGVFHMZRD-UHFFFAOYSA-N N-[[1-(1,3-benzodioxol-5-yl)-2-hydroxyiminoethylidene]amino]-3-chlorobenzamide Chemical compound C=1C=C2OCOC2=CC=1C(C=NO)=NNC(=O)C1=CC=CC(Cl)=C1 JOHRDWGVFHMZRD-UHFFFAOYSA-N 0.000 description 1
- FRQPQKAOBORGDA-UHFFFAOYSA-N N-[[1-(2-bromophenyl)-2-hydroxyiminoethylidene]amino]-4-tert-butylbenzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)NN=C(C=NO)C1=CC=CC=C1Br FRQPQKAOBORGDA-UHFFFAOYSA-N 0.000 description 1
- JBYLPSIBOHBXKI-UHFFFAOYSA-N N-[[1-(2-chlorophenyl)-2-hydroxyiminoethylidene]amino]benzamide Chemical compound C=1C=CC=C(Cl)C=1C(C=NO)=NNC(=O)C1=CC=CC=C1 JBYLPSIBOHBXKI-UHFFFAOYSA-N 0.000 description 1
- HQYRSIUHJPCFDD-UHFFFAOYSA-N N-[[1-(2-fluorophenyl)-2-hydroxyiminoethylidene]amino]-4-phenylbenzamide Chemical compound C=1C=CC=C(F)C=1C(C=NO)=NNC(=O)C(C=C1)=CC=C1C1=CC=CC=C1 HQYRSIUHJPCFDD-UHFFFAOYSA-N 0.000 description 1
- ATOABBJZJQEJJM-UHFFFAOYSA-N N-[[1-(3-bromophenyl)-2-hydroxyiminoethylidene]amino]-3-(dimethylsulfamoyl)benzamide Chemical compound CN(C)S(=O)(=O)C1=CC=CC(C(=O)NN=C(C=NO)C=2C=C(Br)C=CC=2)=C1 ATOABBJZJQEJJM-UHFFFAOYSA-N 0.000 description 1
- HTZTXKUYQIKUCF-UHFFFAOYSA-N N-[[1-(3-chlorophenyl)-2-hydroxyiminoethylidene]amino]-2-methylpyridine-3-carboxamide Chemical compound CC1=NC=CC=C1C(=O)NN=C(C=NO)C1=CC=CC(Cl)=C1 HTZTXKUYQIKUCF-UHFFFAOYSA-N 0.000 description 1
- NRECYGWFOCEASZ-UHFFFAOYSA-N N-[[1-(3-chlorophenyl)-2-hydroxyiminoethylidene]amino]-3-(trifluoromethyl)benzamide Chemical compound C=1C=CC(Cl)=CC=1C(C=NO)=NNC(=O)C1=CC=CC(C(F)(F)F)=C1 NRECYGWFOCEASZ-UHFFFAOYSA-N 0.000 description 1
- XMOFHQOPLBKFGI-UHFFFAOYSA-N N-[[1-(3-chlorophenyl)-2-hydroxyiminoethylidene]amino]-3-fluorobenzamide Chemical compound C=1C=CC(Cl)=CC=1C(C=NO)=NNC(=O)C1=CC=CC(F)=C1 XMOFHQOPLBKFGI-UHFFFAOYSA-N 0.000 description 1
- CAYVBTZXIOXGAA-UHFFFAOYSA-N N-[[1-(3-chlorophenyl)-2-hydroxyiminoethylidene]amino]-3-methylpyridine-2-carboxamide Chemical compound CC1=CC=CN=C1C(=O)NN=C(C=NO)C1=CC=CC(Cl)=C1 CAYVBTZXIOXGAA-UHFFFAOYSA-N 0.000 description 1
- VDOXXSLWSDBITB-UHFFFAOYSA-N N-[[1-(3-chlorophenyl)-2-hydroxyiminoethylidene]amino]-4-methylpyridine-3-carboxamide Chemical compound CC1=CC=NC=C1C(=O)NN=C(C=NO)C1=CC=CC(Cl)=C1 VDOXXSLWSDBITB-UHFFFAOYSA-N 0.000 description 1
- GAXREQPVXYPCHN-UHFFFAOYSA-N N-[[1-(3-chlorophenyl)-2-hydroxyiminoethylidene]amino]-5-methylpyridine-3-carboxamide Chemical compound CC1=CN=CC(C(=O)NN=C(C=NO)C=2C=C(Cl)C=CC=2)=C1 GAXREQPVXYPCHN-UHFFFAOYSA-N 0.000 description 1
- FXTTUXDSVBLVKT-UHFFFAOYSA-N N-[[1-(3-chlorophenyl)-2-hydroxyiminoethylidene]amino]-6-methylpyridine-2-carboxamide Chemical compound CC1=CC=CC(C(=O)NN=C(C=NO)C=2C=C(Cl)C=CC=2)=N1 FXTTUXDSVBLVKT-UHFFFAOYSA-N 0.000 description 1
- BGRYADJZRXJGCZ-UHFFFAOYSA-N N-[[1-(3-chlorophenyl)-2-hydroxyiminoethylidene]amino]benzamide Chemical compound C=1C=CC(Cl)=CC=1C(C=NO)=NNC(=O)C1=CC=CC=C1 BGRYADJZRXJGCZ-UHFFFAOYSA-N 0.000 description 1
- KEZJPVRQZCCVFU-UHFFFAOYSA-N N-[[1-(3-chlorophenyl)-2-hydroxyiminoethylidene]amino]pyrazine-2-carboxamide Chemical compound C=1C=CC(Cl)=CC=1C(C=NO)=NNC(=O)C1=CN=CC=N1 KEZJPVRQZCCVFU-UHFFFAOYSA-N 0.000 description 1
- WRGUEQORVZNOTQ-UHFFFAOYSA-N N-[[1-(4-bromophenyl)-2-hydroxyiminoethylidene]amino]benzamide Chemical compound C=1C=C(Br)C=CC=1C(C=NO)=NNC(=O)C1=CC=CC=C1 WRGUEQORVZNOTQ-UHFFFAOYSA-N 0.000 description 1
- LYXBBYLEPRLMPD-UHFFFAOYSA-N N-[[1-(4-chlorophenyl)-2-hydroxyiminoethylidene]amino]benzamide Chemical compound C=1C=C(Cl)C=CC=1C(C=NO)=NNC(=O)C1=CC=CC=C1 LYXBBYLEPRLMPD-UHFFFAOYSA-N 0.000 description 1
- SOQXQAMJSOHDEC-UHFFFAOYSA-N N-[[2-hydroxyimino-1-(3-hydroxyphenyl)ethylidene]amino]-2-methylbenzamide Chemical compound CC1=CC=CC=C1C(=O)NN=C(C=NO)C1=CC=CC(O)=C1 SOQXQAMJSOHDEC-UHFFFAOYSA-N 0.000 description 1
- OFRCRUGKJUKTHG-UHFFFAOYSA-N N-[[2-hydroxyimino-1-(3-hydroxyphenyl)ethylidene]amino]benzamide Chemical compound C=1C=CC(O)=CC=1C(C=NO)=NNC(=O)C1=CC=CC=C1 OFRCRUGKJUKTHG-UHFFFAOYSA-N 0.000 description 1
- YUHDDMAVKCTUAM-UHFFFAOYSA-N N-[[2-hydroxyimino-1-(3-methoxyphenyl)ethylidene]amino]benzamide Chemical compound COC1=CC=CC(C(C=NO)=NNC(=O)C=2C=CC=CC=2)=C1 YUHDDMAVKCTUAM-UHFFFAOYSA-N 0.000 description 1
- HPHJJYPSPBFMDA-UHFFFAOYSA-N N-[[2-hydroxyimino-1-(3-nitrophenyl)ethylidene]amino]-3-methoxybenzamide Chemical compound COC1=CC=CC(C(=O)NN=C(C=NO)C=2C=C(C=CC=2)[N+]([O-])=O)=C1 HPHJJYPSPBFMDA-UHFFFAOYSA-N 0.000 description 1
- VIPRZXRRVDOBLD-UHFFFAOYSA-N N-[[2-hydroxyimino-1-(3-nitrophenyl)ethylidene]amino]-3-nitrobenzamide Chemical compound C=1C=CC([N+]([O-])=O)=CC=1C(C=NO)=NNC(=O)C1=CC=CC([N+]([O-])=O)=C1 VIPRZXRRVDOBLD-UHFFFAOYSA-N 0.000 description 1
- WPVMMEAURAEYBO-UHFFFAOYSA-N N-[[2-hydroxyimino-1-(4-phenoxyphenyl)ethylidene]amino]-4-phenylbenzamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C(C=NO)=NNC(=O)C(C=C1)=CC=C1C1=CC=CC=C1 WPVMMEAURAEYBO-UHFFFAOYSA-N 0.000 description 1
- NFFBHIKWWMWBNJ-UHFFFAOYSA-N N-[[2-hydroxyimino-1-[3-(trifluoromethyl)phenyl]ethylidene]amino]-4-phenylbenzamide Chemical compound C=1C=CC(C(F)(F)F)=CC=1C(C=NO)=NNC(=O)C(C=C1)=CC=C1C1=CC=CC=C1 NFFBHIKWWMWBNJ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000004474 heteroalkylene group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000001867 hydroperoxy group Chemical group [*]OO[H] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- IOSIZXYVXXVIEO-UHFFFAOYSA-N n-[(1-phenyl-2-phenylmethoxyiminoethylidene)amino]benzamide Chemical compound C=1C=CC=CC=1C(=O)NN=C(C=1C=CC=CC=1)C=NOCC1=CC=CC=C1 IOSIZXYVXXVIEO-UHFFFAOYSA-N 0.000 description 1
- VWRYIRHVODCMBO-UHFFFAOYSA-N n-[(1-phenyl-2-propoxyiminoethylidene)amino]benzamide Chemical compound C=1C=CC=CC=1C(C=NOCCC)=NNC(=O)C1=CC=CC=C1 VWRYIRHVODCMBO-UHFFFAOYSA-N 0.000 description 1
- HQGOYBHDHCVCFW-UHFFFAOYSA-N n-[(2-ethoxyimino-1-phenylethylidene)amino]benzamide Chemical compound C=1C=CC=CC=1C(C=NOCC)=NNC(=O)C1=CC=CC=C1 HQGOYBHDHCVCFW-UHFFFAOYSA-N 0.000 description 1
- GIWQIJXMVMQPNY-UHFFFAOYSA-N n-[3-(2-hydroxyiminoacetyl)phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C(=O)C=NO)=C1 GIWQIJXMVMQPNY-UHFFFAOYSA-N 0.000 description 1
- HPPCYBIAHRKKCQ-UHFFFAOYSA-N n-[[1-(3-chlorophenyl)-2-ethoxyiminoethylidene]amino]benzamide Chemical compound C=1C=CC(Cl)=CC=1C(C=NOCC)=NNC(=O)C1=CC=CC=C1 HPPCYBIAHRKKCQ-UHFFFAOYSA-N 0.000 description 1
- NKPVLCMDXUGHHU-UHFFFAOYSA-N n-[[2-(2-methoxyethoxyimino)-1-phenylethylidene]amino]benzamide Chemical compound C=1C=CC=CC=1C(C=NOCCOC)=NNC(=O)C1=CC=CC=C1 NKPVLCMDXUGHHU-UHFFFAOYSA-N 0.000 description 1
- WYMNWUHBXCPTGX-UHFFFAOYSA-N n-[[2-(2-methylpropoxyimino)-1-phenylethylidene]amino]benzamide Chemical compound C=1C=CC=CC=1C(C=NOCC(C)C)=NNC(=O)C1=CC=CC=C1 WYMNWUHBXCPTGX-UHFFFAOYSA-N 0.000 description 1
- KYCXEHBUAPDSLH-UHFFFAOYSA-N n-[[2-(3-methylbutoxyimino)-1-phenylethylidene]amino]benzamide Chemical compound C=1C=CC=CC=1C(C=NOCCC(C)C)=NNC(=O)C1=CC=CC=C1 KYCXEHBUAPDSLH-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000001166 thiolanyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54914304P | 2004-03-03 | 2004-03-03 | |
| PCT/GB2005/000780 WO2005084656A1 (en) | 2004-03-03 | 2005-03-02 | Use of new lipoxygenase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007526290A true JP2007526290A (ja) | 2007-09-13 |
| JP2007526290A5 JP2007526290A5 (enExample) | 2008-04-17 |
Family
ID=34919440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007501342A Withdrawn JP2007526290A (ja) | 2004-03-03 | 2005-03-02 | 新規のリポキシゲナーゼインヒビターの使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080227787A1 (enExample) |
| EP (1) | EP1725227A1 (enExample) |
| JP (1) | JP2007526290A (enExample) |
| WO (1) | WO2005084656A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107043345B (zh) * | 2017-06-20 | 2019-07-05 | 齐鲁工业大学 | 联苯乙酮腙-吲哚啉-2,3-二酮西弗碱的制备、结构和用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2767192A (en) * | 1951-12-22 | 1956-10-16 | Schenley Ind Inc | Ketone hydrazones |
-
2005
- 2005-03-02 EP EP05717858A patent/EP1725227A1/en not_active Withdrawn
- 2005-03-02 US US10/590,450 patent/US20080227787A1/en not_active Abandoned
- 2005-03-02 WO PCT/GB2005/000780 patent/WO2005084656A1/en not_active Ceased
- 2005-03-02 JP JP2007501342A patent/JP2007526290A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005084656A1 (en) | 2005-09-15 |
| EP1725227A1 (en) | 2006-11-29 |
| US20080227787A1 (en) | 2008-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4116058B2 (ja) | プロスタグランジンｅ２拮抗薬としてのフェニルまたはピリジルアミド化合物 | |
| JP4373497B2 (ja) | 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用 | |
| US6441000B1 (en) | Compounds useful in therapy | |
| US20100004301A1 (en) | Benzoxazoles Useful in the Treatment of Inflammation | |
| JP2008527029A (ja) | 炎症の治療に有用なインドール類 | |
| OA10985A (en) | Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) | |
| WO2008129276A1 (en) | Disulfonamides useful in the treatment of inflammation | |
| US7705023B2 (en) | Indoles useful in the treatment of inflammation | |
| JP2008527028A (ja) | 炎症の治療に有用なインドール類 | |
| JP2006520373A (ja) | 炎症の治療に有用なピラゾール化合物 | |
| JP2010520268A (ja) | 炎症の治療に有用な新しいメチレンビスフェニル化合物 | |
| JP2008502670A (ja) | 炎症の治療に有用なインドール類 | |
| WO2005005415A1 (en) | Indoles useful in the treatment of inflammation | |
| US20090186918A1 (en) | Triazole Compounds as Lipoxygenase Inhibitors | |
| JP2009511559A (ja) | 炎症の治療に有用なベンゾオキサゾール類 | |
| US20130035358A1 (en) | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | |
| US20060183780A1 (en) | Pyrazole compounds useful in the treatment of inflammation | |
| JP2008513427A (ja) | 炎症の治療に有用なピラゾール化合物 | |
| JP2007526290A (ja) | 新規のリポキシゲナーゼインヒビターの使用 | |
| US20120035217A1 (en) | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | |
| JP2008502672A (ja) | 炎症の治療に有用なインドール類 | |
| US20090088463A1 (en) | Pyrazoles Useful in the Treatment of Inflammation | |
| JP2012520276A (ja) | Ｌｔｃ４シンターゼ阻害剤としての使用のためのビス芳香族化合物 | |
| CN119894899A (zh) | 用作泛素-特异性蛋白酶抑制剂的羰基稠合杂环衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080229 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080229 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20090629 |